• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC CRYOCATH LP FREEZOR MAX CARDIAC CRYOABLATION CATHETER; PERCUTANEOUS CATHETER INTENDED FOR TREATMENT OF ATRIAL FIBRILLATION

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC CRYOCATH LP FREEZOR MAX CARDIAC CRYOABLATION CATHETER; PERCUTANEOUS CATHETER INTENDED FOR TREATMENT OF ATRIAL FIBRILLATION Back to Search Results
Model Number 209F3
Device Problem Difficult To Position (1467)
Patient Problem No Code Available (3191)
Event Type  Injury  
Manufacturer Narrative
Medtronic (b)(4) was made aware of this event through a search of literature publications.It was not possible to ascertain specific device information from the literature publication or to match the event with previously reported events.This information is based entirely on journal literature.This event occurred outside the us.All information provided is included in this report.Patient information is limited due to confidentiality concerns.The baseline gender/age is male/(b)(6) years old.Without a lot number or device serial number, the manufacturing date cannot be determined.Since no device id was provided, it is unknown if this event has been previously reported.Referenced article: comparison of 'anatomically designed' and 'pointby-point' catheter ablations for human atrial fibrillation in terms of procedure timing and costs in german hospitals.Europace.2015;17(7):1030-1037.(b)(4).
 
Event Description
A journal article was received which contained information regarding cardiac ablation sheaths and catheters.Multiple patients were noted in the article; however, a one to one correlation could not be made with unique device serial numbers.The literature publication reports the following complications: pericardial effusion, hematoma, and difficulty positioning the catheter which resulted in longer procedure time.The status of the product is unknown.No further patient complications have been reported as a result of this event.Klein g, lickfett l, schreieck j, et al.Comparison of 'anatomically designed' and 'pointby-point' catheter ablations forhuman atrial fibrillation in terms of procedure timing and costs in german hospitals.Europace.2015;17(7):1030-1037.Aims the purpose of the fast-pvi study was to compare 'traditional' ablation tools based on 'point-by-point' technology with the new 'anatomically designed' technologies in terms of procedure times and related costs for the treatment of paroxysmal atrial fibrillation.Methods and results four hundred and fifty-two consecutive ablation procedures (222 'anatomically designed', 136 arctic front<(><<)>sup>><<)>/sup> and 86 pvac<(><<)>sup>> <<)>/sup>) and 230 'point-by-point' ablations (100 carto xp and 130 navx navigation systems) performed by nine university centres across germany from 2006 to 2010 were evaluated retrospectively.Staffing and resources times for each procedure were documented together with patient morbidities, complications, and pulmonary veins isolations.On the basis of drg data from 2006 to 2010, human resources use and equipment maintenance costs were assigned to ablation procedure and calendar year.All procedural times were significantly higher in 'point-by-point' technologies compared with 'anatomically designed' ablations [average lab occupancy time 185.30 vs.280.28 min; physician time 152.21 vs.238.04 min; support time 183.43 vs.278.34 min and fluoroscopy time 29.11 vs.40.72 min; p <(><<)> 0.001 (95% confidence interval, ci)].For each ablation procedure human resource use per operating minute resulted in lower costs for 'anatomically designed' ablations [(b)(4)].Savings due to reduced duration in 'anatomically designed' technologies accrued to (b)(4)lower human resource costs.Sensitivity analyses did not lead to any significant variations on the outcomes parameter cost per minute.Conclusion fast-pvi showed reductions in ablation procedural time may lead to increased hospital capacity and non-device-related cost-savings, while maintaining quality.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
FREEZOR MAX CARDIAC CRYOABLATION CATHETER
Type of Device
PERCUTANEOUS CATHETER INTENDED FOR TREATMENT OF ATRIAL FIBRILLATION
Manufacturer (Section D)
MEDTRONIC CRYOCATH LP
16771 chemin ste-marie
kirkland H9H 5 H3
CA  H9H 5H3
Manufacturer (Section G)
MEDTRONIC CARDIAC RHYTHM HEART FAILURE
8200 coral sea st ne
mounds view MN 55112
Manufacturer Contact
anne schilling
8200 coral sea st ne
mounds view, MN 55112
7635052036
MDR Report Key5051915
MDR Text Key24902263
Report Number3002648230-2015-00269
Device Sequence Number1
Product Code OAE
Combination Product (y/n)N
Reporter Country CodeGM
PMA/PMN Number
P100010
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Report Date 08/05/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/02/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model Number209F3
Device Catalogue Number209F3
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/05/2015
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age00058 YR
-
-